Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967361 | 1.00 | PSMB8 (0.50) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL341252 | 0.75 | PDE3B (0.49) | ALDH1A1AURKAPARP1DAO | |
| SCHEMBL30775064 | 0.69 | PSMB8 (0.48) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL1002214 | 0.69 | PSMB8 (0.48) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| 2-Mercaptobenzothiazole SCHEMBL29433968 | 0.67 | PSMB8 (1.00) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| 2-Mercaptobenzothiazole SCHEMBL408087 | 0.67 | PSMB8 (1.00) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| 2-Mercaptobenzothiazole SCHEMBL4268289 | 0.65 | PSMB8 (0.95) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| 2-Mercaptobenzothiazole SCHEMBL29729650 | 0.65 | PSMB8 (0.95) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| 2-Mercaptobenzothiazole SCHEMBL8749352 | 0.65 | PSMB8 (0.95) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| 2-Mercaptobenzothiazole SCHEMBL5934103 | 0.65 | PSMB8 (0.95) | PSMB8KDM4EALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113824-A1 | BICYCLIC (THIO)CARBONYLAMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2707373-A1 | BICYCLIC (THIO)CARBONYLAMIDINES | Bayer Intellectual Property GmbH (DE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152741-A1 | BICYCLIC (THIO)CARBONYLAMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-15 | — | — | WO | disclosed |
| US-8283360-B2 | Bicyclic heterocyclic derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283360-B2 | Bicyclic heterocyclic derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110319434-A1 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof | SCHERING PLOUGH CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319434-A1 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof | SCHERING PLOUGH CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| EP-1805156-B1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759376-B2 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1805156-A4 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORP (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1805156-A2 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044775-A2 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265298-A1 | Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, PGC | PSMB8 2981/4885KDM4E 278/4885ALDH1A1 93/4885 |
| US-20110118302-A1 | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, PGC | PSMB8 2981/4885KDM4E 278/4885ALDH1A1 93/4885 |
| US-20110319434-A1 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof | GPR119, GID4, TLR4 | PSMB8 3459/4885KDM4E 3960/4885ALDH1A1 1161/4885 |
| US-20140113824-A1 | BICYCLIC (THIO)CARBONYLAMIDINES | BROX, BOLA2; BOLA2B, CAT | PSMB8 1558/4885KDM4E 1905/4885ALDH1A1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.